News Room
News Room
News Room
Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
Expansion builds on initial strategic collaboration and license agreement Chicago, April 5, 2022 – Evozyne, Inc., an adaptive biology company [...]
Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation
License agreement secures potential research of ecopipam for one of the most common neurological sensory disorders Chicago, March 1, 2022 – Emalex Biosciences, Inc. [...]
Outstanding 2021 for Paragon Biosciences and Our Portfolio Companies
Chicago, Dec. 16, 2021 – Paragon Biosciences has had a stellar year of achievements in 2021, advancing our mission to solve some of society’s most [...]
PARAGON BIOSCIENCES EARNS 2021 GREAT PLACE TO WORK™ CERTIFICATION
Chicago, Dec. 7, 2021 – Paragon Biosciences is proud to announce that it has been certified as a Great Place to Work®. This prestigious [...]
Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome
Statistically significant, clinically meaningful results obtained on the primary and multiple secondary efficacy endpoints; ecopipam well tolerated in the study Chicago, Nov. 10, 2021 [...]
Emalex Biosciences Recruiting People Who Stutter for Phase 2 Clinical Trial for Childhood-Onset Fluency Disorder
Current enrollment for stuttering study is at 75%; Nine U.S. Sites Nationwide Chicago, September 14, 2021 – Emalex Biosciences, Inc. (“Emalex”), a biopharmaceutical company [...]
